Altimmune's pemvidutide hits its primary endpoint in the Phase 2 RECLAIM trial, cutting heavy drinking days vs. placebo in alcohol use disorder (p=0.0014).
Altimmune said Tuesday that its GLP-1/glucagon agonist reduced drinking in people with moderate-to-severe alcohol use disorder in a mid-stage study.
Patients in the Phase 2 …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Altimmune reports positive Phase 2 RECLAIM trial data for pemvidutide in AUD and plans to request an EOP2 meeting with the FDA.
People with alcohol use disorder taking oral semaglutide saw numerous improvements compared to placebo, a recent clinical trial…
More than 27 million Americans suffer from the devastating condition which can destroy physical and mental health, as well as…
Alcoholics given semaglutide reduced alcohol consumption, had fewer heavy drinking days and saw a reduction in alcohol cravings
Can Oral Semaglutide Reduce Alcohol Use? CU Anschutz Clinical Trial Shows Fewer Heavy Drinking Days
The study aims to enroll more than 600 veterans at 18 VA medical centers.
Altimmune Lead Drug Study Shows Significant Alcohol Reduction - Altimmune (NASDAQ:ALT)
A Daily GLP-1 Pill Could Curb Heavy Drinking
GLP-1 pill can reduce heavy drinking in adults with alcohol use disorder: study
Can Oral Semaglutide Reduce Alcohol Use? CU Anschutz Clinical Trial Shows Fewer Heavy Drinking Days
VA to run trial of GLP-1 drug to treat alcohol abuse
The Drug Behind Ozempic Pill May Help Treat Alcoholics
La semaglutide in pillola riduce anche il consumo di alcol, oltre al peso: lo studio
GLP-1s and Alcohol Use Disorder; No Luck With Gonorrhea Vaccine
